Literature DB >> 19669248

The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression.

Munechika Enjoji, Ryoko Yada, Tatsuya Fujino, Tsuyoshi Yoshimoto, Masayoshi Yada, Naohiko Harada, Nobito Higuchi, Masaki Kato, Motoyuki Kohjima, Akinobu Taketomi, Yoshihiko Maehara, Manabu Nakashima, Kazuhiro Kotoh, Makoto Nakamuta.   

Abstract

AIM: Because dyslipidemia, such as hypercholesterolemia, is a characteristic of primary biliary cirrhosis (PBC), hepatic lipid metabolism may be disturbed in PBC patients. We examined the expression of lipid metabolism-associated genes in PBC liver.
METHODS: All of the patients examined were in stage I or II PBC and without medication. RNA was isolated from liver specimens by needle biopsies of PBC patients and controls. The expression levels of various genes were measured by real-time RT-PCR. Multidrug resistance 3 (MDR3) expression was examined immunohistochemically. Statistical correlations between the gene expression levels and indices of blood testing were calculated.
RESULTS: The expression levels of sterol regulatory element-binding protein (SREBP) 2 and LDL receptor were significantly lower, and those of apolipoprotein B, microsomal triglyceride transfer protein, ATP-binding cassette G5, and liver X receptor α (LXRα) were significantly higher in the PBC liver than in the normal control liver. The expression levels of bile acid synthesis- and excretion-associated genes did not change, and those of farnesoid X receptor, peroxisome proliferator-activated receptor α, and SREBP-1c were similar between the PBC and normal liver. MDR3 gene expression levels in the PBC liver were more than 4-fold higher than those in the control liver. Immunohistochemically, strong canalicular staining for MDR3 was observed in the PBC liver. LXRα expression was positively correlated with MDR3 levels. Serum levels of γ-glutamyl transpeptidase (GGT) and IgM were negatively correlated with MDR3 levels.
CONCLUSIONS: Hepatocellular cholesterol metabolism was at least partially disturbed, even in the early stage of PBC. The most characteristic finding was a distinct elevation of MDR3 expression, and the MDR3 levels were negatively correlated with GGT and IgM levels.

Entities:  

Year:  2009        PMID: 19669248      PMCID: PMC2748377          DOI: 10.1007/s12072-009-9137-y

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  20 in total

1.  Reduced hepatic expression of adipose tissue triglyceride lipase and CGI-58 may contribute to the development of non-alcoholic fatty liver disease in patients with insulin resistance.

Authors:  Masaki Kato; Nobito Higuchi; Munechika Enjoji
Journal:  Scand J Gastroenterol       Date:  2008-08       Impact factor: 2.423

Review 2.  Protein sensors for membrane sterols.

Authors:  Joseph L Goldstein; Russell A DeBose-Boyd; Michael S Brown
Journal:  Cell       Date:  2006-01-13       Impact factor: 41.582

3.  Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate.

Authors:  Takayuki Matsumoto; Hiroaki Miyazaki; Yoshitsugu Nakahashi; Junko Hirohara; Toshihito Seki; Kyoichi Inoue; Kazuichi Okazaki
Journal:  Hepatol Res       Date:  2004-11       Impact factor: 4.288

Review 4.  Cholesterol and non-cholesterol sterol transporters: ABCG5, ABCG8 and NPC1L1: a review.

Authors:  S Kidambi; S B Patel
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

5.  Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4.

Authors:  Junichi Shoda; Yoichi Inada; Atsutoshi Tsuji; Hiroshi Kusama; Tetsuya Ueda; Tadashi Ikegami; Hiroshi Suzuki; Yuichi Sugiyama; David E Cohen; Naomi Tanaka
Journal:  J Lipid Res       Date:  2004-07-16       Impact factor: 5.922

6.  Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis.

Authors:  Yuki Ohishi; Minoru Nakamura; Naomi Iio; Shingo Higa; Mao Inayoshi; Yoshihiro Aiba; Atsumasa Komori; Katsuhisa Omagari; Hiromi Ishibashi; Kazuhiro Tsukamoto
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

Review 7.  Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism.

Authors:  Grazyna Wójcicka; Anna Jamroz-Wiśniewska; Krzysztof Horoszewicz; Jerzy Bełtowski
Journal:  Postepy Hig Med Dosw (Online)       Date:  2007-12-03       Impact factor: 0.270

8.  Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.

Authors:  Gernot Zollner; Peter Fickert; Dagmar Silbert; Andrea Fuchsbichler; Hanns Ulrich Marschall; Kurt Zatloukal; Helmut Denk; Michael Trauner
Journal:  J Hepatol       Date:  2003-06       Impact factor: 25.083

9.  Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice.

Authors:  Junichi Shoda; Kosuke Okada; Yoichi Inada; Hiroshi Kusama; Hirotoshi Utsunomiya; Koji Oda; Tsuyoshi Yokoi; Katsutoshi Yoshizato; Hiroshi Suzuki
Journal:  Hepatol Res       Date:  2007-07       Impact factor: 4.288

10.  Fenofibrate for patients with asymptomatic primary biliary cirrhosis.

Authors:  Kazufumi Dohmen; Toshihiko Mizuta; Makoto Nakamuta; Naoya Shimohashi; Hiromi Ishibashi; Kyosuke Yamamoto
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

View more
  6 in total

Review 1.  Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?

Authors:  Munechika Enjoji; Makoto Nakamuta
Journal:  World J Gastroenterol       Date:  2010-02-21       Impact factor: 5.742

2.  NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.

Authors:  Munechika Enjoji; Kazuyuki Machida; Motoyuki Kohjima; Masaki Kato; Kazuhiro Kotoh; Kazuhisa Matsunaga; Manabu Nakashima; Makoto Nakamuta
Journal:  Lipids Health Dis       Date:  2010-03-12       Impact factor: 3.876

3.  Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol.

Authors:  Munechika Enjoji; Kenichiro Yasutake; Motoyuki Kohjima; Makoto Nakamuta
Journal:  Int J Hepatol       Date:  2012-04-05

4.  Risk of Cardiovascular Events in Patients with Primary Biliary Cholangitis - Systematic Review.

Authors:  Duminda Suraweera; Christina Fanous; Melissa Jimenez; Myron J Tong; Sammy Saab
Journal:  J Clin Transl Hepatol       Date:  2018-02-14

5.  Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism.

Authors:  Songsong Wang; Feiya Sheng; Liang Zou; Jianbo Xiao; Peng Li
Journal:  J Adv Res       Date:  2021-06-08       Impact factor: 10.479

6.  Hepatobiliary anomalies associated with ABCB4/MDR3 deficiency in adults: a pictorial essay.

Authors:  Julie Benzimra; Sarah Derhy; Olivier Rosmorduc; Yves Menu; Raoul Poupon; Lionel Arrivé
Journal:  Insights Imaging       Date:  2013-04-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.